Skip to main content
. Author manuscript; available in PMC: 2024 Jun 1.
Published in final edited form as: Am J Hematol. 2023 Apr 6;98(6):932–939. doi: 10.1002/ajh.26924

Figure 1. Relapse and Clonal Evolution after Alemtuzumab.

Figure 1.

Cumulative incidence curves were used to estimate the probability of relapse and clonal evolution after alemtuzumab, with death as a competing risk. Relapse and clonal evolution for the overall cohort (A, C) and divided by route of administration (B, D) are shown. The cumulative incidence of SAA relapse following alemtuzumab at median time of follow-up of 6 years (2180 days), was 39%. Clonal evolution occurred in 9 patients, with cumulative incidence of 23% at the median follow-up of 6 years (2180 days). Evolvers had a median time to evolution of over 2 years (755 days) following alemtuzumab administration. There was no significant difference seen in relapse or clonal evolution by route of administration.

Abbreviations: IV = intravenous; SC = subcutaneous